Ferinject® approved in Chinafor the treatment of iron deficiency in adult patients
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221127005020/en/
CSL Vifor and Fresenius Kabi today announced that China’s National Medical Products Administration (NMPA) has approved Ferinject®, a preparation for intravenous iron therapy for the treatment of iron deficiency in adult patients for whom oral iron preparations are ineffective, oral iron preparations cannot be used or for whom there is a clinical need to deliver iron rapidly. Ferinject® has now received marketing authorization in 85 countries worldwide.
“We are thrilled about the marketing authorization of Ferinject®, which is a milestone for Chinese patients living with iron deficiency or iron deficiency anemia”, said Hervé Gisserot, General Manager of CSL Vifor. “There is a high unmet need in China, which has the world’s largest iron deficiency population, and we are confident that Ferinject® can make a meaningful difference in the treatment of these patients. At the same time, this is another important step in our goal to globalizing and maximizing the performance of our iron franchise as we look forward to bring this treatment to market as soon as possible.”
“Marketing authorization of Ferinject® will strengthen our commitment of bringing innovative medicines for patients in China. We are guided by our corporate philosophy of caring for life and invested to putting essential medicines and technologies in the hands of people who help patients and to finding the best answers to the challenges they face”, said Yang Weiping, President of Fresenius Kabi China.
The approval of Ferinject® may also enable a more effective implementation of PBM in Chinese hospitals, where an estimated 3-4 million patients undergo elective surgery each year. In China, PBM encompasses multiple in-hospital procedures across therapeutic areas. The China National Health Commission (NHC) has announced guidelines for perioperative PBM as a health standard across China, effective as per 1 June 2022.
Marketing authorization in China is based on positive clinical results from the phase-III trial VIT-IRON-2011-004. This open label, randomized multicenter study showed that Ferinject® is an effective and well-tolerated alternative to iron sucrose for the treatment of iron deficiency anemia that can provide an improved hemoglobin response and correction of iron deficiency in Chinese patients.
CSL Vifor and Fresenius Kabi currently expect to begin to market Ferinject® in the first half of 2023, with National Reimbursement Drug List (NRDL) listing anticipated in January 2024.
About CSL Vifor
CSL Vifor is a global partner of choice for pharmaceuticals and innovative, leading therapies in iron deficiency, dialysis and nephrology & rare disease. We specialize in strategic global partnering, in-licensing and developing, manufacturing and marketing pharmaceutical products for precision healthcare, aiming to help patients around the world lead better, healthier lives. Headquartered in St. Gallen, Switzerland, CSL Vifor also includes the joint company Vifor Fresenius Medical Care Renal Pharma (with Fresenius Medical Care).
The parent company, CSL (ASX:CSL; USOTC:CSLLY), headquartered in Melbourne, Australia, employs 30,000 people and delivers its lifesaving therapies to people in more than 100 countries. For more information about CSL Vifor visit, www.cslvifor.com.
About Fresenius Kabi
Fresenius Kabi is a global healthcare company that specializes in lifesaving medicines and technologies for infusion, transfusion and clinical nutrition. The company’s products and services are used to help care for critically and chronically ill patients. Fresenius Kabi’s product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the devices for administering these products. In the field of biosimilars, Fresenius Kabi focuses on autoimmune diseases and oncology. In 2019, the first biosimilar product by Fresenius Kabi was launched. Within transfusion medicine and cell therapies, Fresenius Kabi offers products for collection of blood components and extracorporeal therapies.
With its corporate mission of "caring for life", the company is committed to putting essential medicines and technologies in the hands of people who help patients and finding the best answers to the challenges they face. For more information, please visit www.fresenius-kabi.com.
About Ferinject®
Ferinject®/Injectafer® (ferric carboxymaltose) is an i.v. iron therapy with market authorization in 85 countries by November 2022. More than 19 million patient years of experience have helped to establish Ferinject®/ Injectafer® as a trusted brand, with clinical benefits demonstrated by its efficacy and safety data2. Ferinject’s® quality relies on a consistent and firmly-controlled manufacturing process based on decades of experience.
About iron deficiency
Iron Deficiency affects about half of the patients with chronic kidney disease3 and chronic heart failure and is associated with reduced quality of life4, an increased risk of hospitalization5 and cardiovascular death6. Despite the serious consequences and high prevalence, of iron deficiency, the condition remains under-recognized7.
Iron plays a vital role in many bodily processes, including the production of red blood cells, effective heart and brain function, and the prevention of infection and illness. Without enough iron, the body is unable to function properly. Common symptoms include fatigue, dizziness, and shortness of breath. Iron deficiency and iron deficiency anemia is estimated to affect one in three people worldwide8, yet despite the serious consequences and high prevalence9, it remains an under-recognized condition.
Although iron deficiency can affect anyone, it is most prevalent in premenopausal women, pregnant woman and children under five10. Left untreated, it can develop into iron deficiency anemia. The effects of iron deficiency differ from person to person but can be linked to an overall decline in general health and well-being11. Even without anemia, iron deficiency can be debilitating, exacerbate an underlying chronic disease and lead to increased morbidity and mortality12. Common symptoms include fatigue11, 13, 14 pale skin13, brittle nails13, 15, craving non-food items such as dirt, clay and ice16, and an inability to concentrate11, 17. In children, iron deficiency can significantly impair cognitive and motor development18.
About Patient Blood Management (PBM)
PBM is designed to improve surgical and medical patient outcomes by optimally managing and preserving patients’ blood. Proactive identification and treatment of iron deficiency anemia in patients scheduled for elective surgery has been associated with a reduced need for blood transfusion19 , reduced length of hospital stay19, improved patient’s outcomes20, and overall healthcare expenditure reduction21.
References:
1. Ni W, Yuan X, Sun Y, et al. Anaemia and associated factors among older adults in an urban district in China: a large-scale crosssectional study. BMJ Open 2022;12:e056100. doi:10.1136/ bmjopen-2021-056100.
2. Scott Drugs. 2018 Mar;78(4):479–493. doi: 10.1007/ s40265-018-0885-7.
3. Wong MMY et al. Clin Kid J 2019:1–12; Rocha BML, et al. J Am Coll Cardiol. 2018;71(7):782–793.
4. Guedes M NDT 2021. doi: 10.1093/ndt/gfab050; Enjuanes C, et al. Int J Cardiol. 2014;174(2):268–275.
5. Guedes et al. J Am Soc Nephrol. 2021 Aug;32(8):2020-2030, Martens P, et al. Acta Cardiol. 2018;73(2):115–123.
6. Guedes et al. J Am Soc Nephrol. 2021 Aug;32(8):2020-2030; Klip IT, et al. Am Heart J. 2013;165:575–82.e3.
7. Eur J Heart Fail. 2021 Sep 3. doi: 10.1002/ejhf.2338.
8. Peyrin-Biroulet L, et al. Guidelines on the diagnosis and treatment of iron deficiency across indications: a systematic review. Am J Clin Nutr. 2015;102(6):1585-94.
9. World Health Organization. Worldwide prevalence of anaemia 1993-2005. 2008. Available at URL: http://apps.who.int/iris/bitstream/handle/10665/43894/9789241596657_eng.pdf;jsessionid=9C613E2F4D481EDEB9DE07986AFCE0C7?sequence=1. Last accessed: June 2018.
10. Hercberg S, et al. Iron deficiency in Europe. Public Health Nutr. 2007;4(2b).
11. Fernando B, et al. A guide to diagnosis of iron deficiency and iron deficiency anemia in digestive diseases. World J Gastroenterol. 2009 Oct 7; 15(37): 4638-4643.
12. Cappellini MD et al. Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and management. Am J Hematol. 2017 Oct;92(10):1068-1078.
13. Auerbach M, Adamson JW. How we diagnose and treat iron deficiency anemia. Am J Hematol. 2016;91(1):31-38.
14. Favrat, B., et al. (2014). Evaluation of a single dose of ferric carboxymaltose in fatigued, iron-deficient women--PREFER a randomized, placebo-controlled study. PLoS One 9(4): e94217. eCollection 2014.
15. Cashman MW, Sloan SB. Nutrition and nail disease. Clin Dermatol. 2010;28(4):420-5.
16. Barton JC, et al. Pica associated with iron deficiency or depletion: clinical and laboratory correlates in 262 non-pregnant adult outpatients. BMC Blood Disord. 2010;10:9. doi:10.1186/1471-2326-10-9.
17. Patterson A et al. Iron deficiency, general health and fatigue: Results from the Australian Longitudinal Study on Women’s Health. Qual Life Res. 2000;9:491-497.
18. World Health Organization. Nutritional anaemias: tools for effective prevention and control. 2017. Available at URL: http://www.who.int/nutrition/publications/micronutrients/anaemias-tools-prevention-control/en/. Last accessed: June 2018.
19. Froessler B. et al., Ann Surg 2016
20. Kotzé A. et al., British Journal of Anaesthesia 2012
21. Basora M. et al., Blood Transfus 2018
# # #
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221127005020/en/
Contact information
CSL Vifor Media Contact
Thomas Hutter
Mobile: +41 79 957 96 73
Email: media@viforpharma.com
CSL Investor Contact
Steve McKeon
Associate Director, Investor Relations
CSL Limited
Mobile +61 402 231 696
Email: stephen.mckeon@csl.com.au
Fresenius Kabi contacts:
China Corporate Communications
+86 010 – 59096999
cn.communications@fresenius-kabi.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ICD 2025: New data demonstrate Nemluvio ® ’s (nemolizumab) favorable safety profile and sustained and clinically meaningful improvements in symptoms of prurigo nodularis up to two years18.6.2025 08:00:00 EEST | Press release
Galderma (SIX: GALD) today announced data from a new interim analysis of a study investigating the long-term safety and efficacy of Nemluvio in moderate-to-severe prurigo nodularis. The new data show Nemluvio is well tolerated and associated with sustained and clinically meaningful improvements in symptoms including itch and skin lesions, during prolonged treatment up to two years.1 These new data will be presented as a late-breaking session at ICD, on Saturday, June 21, 2025 at 08:30 AM CET. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250617336479/en/ “These promising data go even further in highlighting the extensive benefits of Nemluvio. As this treatment becomes available in more countries around the world, it’s highly encouraging to see its robust evidence base continue to expand and strengthen.” BALDO SCASSELLATI SFORZOLINI, M.D., PHD. GLOBAL HEAD OF RESEARCH & DEVELOPMENT GALDERMA Prurigo nodularis is a chronic, de
LabPMM ® Receives New York State Approval for the NPM1 MRD Assay - Informing Therapy and Accelerating Targeted Trials18.6.2025 07:30:00 EEST | Press release
Invivoscribe is happy to announce that its wholly owned subsidiary, the Laboratory for Personalized Molecular Medicine® (LabPMM) has received approval from New York State (NYS) for the NPM1 MRD Assay. This approval comes just two months after gaining NYS approval for our FLT3 ITD MRD Assay. Together these tests represent a critical tool for patients with acute myeloid leukemia (AML), clinicians and pharmaceutical companies. This new approval underscores Invivoscribe’s ongoing commitment to providing the most accurate, standardized measurable residual disease (MRD) testing solutions worldwide. The NPM1 MRD Assay is a pivotal development in the fight against AML, offering an ultra-sensitive DNA sequencing method to accurately measure trace levels of residual leukemia cells in patients with the NPM1 mutation variants. NPM1 mutations are considered an ideal target for MRD assessment because they are present in ~30% of adult AML cases,1 stable over time,2 and, if present in blood at allele
DNP to Take Controlling-Stake in Laxton18.6.2025 04:30:00 EEST | Press release
Dai Nippon Printing Co., Ltd. (DNP, TOKYO: 7912) entered into a share transfer agreement on June 17, 2025 to acquire Cayman Islands-headquartered Rubicon SEZC. Rubicon (a holding company of “Laxton” group) is a global Identity Systems Integrator that provides ID solutions for governments, primarily in developing nations, to register and authenticate personal information. DNP plans to acquire 75% of Rubicon's shares in July and complete the procedures to make the company a Group company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250613922077/en/ Products of Laxton DNP will maximize synergies with Laxton in ID cards and card printers. By expanding to government-related business in Africa, Asia, South America, and other regions, we will further grow our authentication and security business, contributing to a safe and secure Smart Society. [About Laxton] Laxton develops ID authentication services using biometric information
DNP: Operational Launch of 2,500 mm-Width Coating Line to Enhance Production Capacity by 15%18.6.2025 04:20:00 EEST | Press release
Dai Nippon Printing Co., Ltd. (DNP) is pleased to announce the September operational launch of a coating device compatible with 2,500 mm-width high functional optical film at our Mihara Plant in Hiroshima Prefecture. The operational launch of the second wide coating device comes in response to market and consumer needs, and will boost production capacity by more than 15% on an area basis. With the increased capacity, DNP will accommodate the demand for high functional optical film for 65-inch large-screen TVs, with horizontal and vertical dimensions of 1,436.4 mm x 809.0 mm, which are expected to increase at a compound annual growth rate (CAGR) of approximately 6% between 2025 and 20301 on an area basis. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250613720341/en/ Image of Mihara Plant [Features] Facilitates the efficient manufacture, or imposition, of high function optical film for 65 inch large screen displays. Designed
Alipay Enables In-Store Payment Functionality in China for AR Glasses in Collaboration with Rokid to Build Immersive Commerce18.6.2025 03:27:00 EEST | Press release
Rokid, a pioneer in augmented reality (AR), today launched Rokid Glasses, its latest AR device. In China, the product supports in-store payments facilitated by Alipay’s digital payment technology and multidimensional risk control solution for AR glasses, providing a seamless and secure payment experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250617845457/en/ Rokid partners with Alipay to launch China’s first AR glasses with in-store payment capabilities. According to Rokid, the product will begin rolling out to users starting in June 2025, with over 250,000 units already ordered. How Payment via AR Glasses Works: Users link their Alipay account via the Rokid app and enable voice verification. In stores, they say: “Rokid, pay 10 RMB.” The glasses scan the merchant’s Alipay QR code. Users confirm by voice, with payment details shown on the display. Advantages of Payment via AR Glasses: Transactions complete in second
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom